Aptose Biosciences advances its Phase 1/2 TUSCANY trial, escalating tuspetinib dosing after a favorable safety review. Enrollment continues across U.S. sites.

ASML’s competitive advantage and strong financials make it a buy. Learn why ASML stock’s reliance on top customers and AI ...

In our analysis, these 12 brokerage accounts stand out as the best choices for stock trading, due to their low fees, strong platforms and quality customer support. Many, or all, of the products ...

Electronic system and device provider Bel Fuse (NASDAQ:BELFA) reported Q4 CY2024 results , with sales up 7% year on year to ...

Alphabet is the cheapest Mag 7 stock, with a forward P/E ratio of only 18.2 for the fiscal year ending 2026. Click here to ...

The shares have sprung back to life thanks to China’s new stimulus programs—and Alibaba’s AI ventures. They stand to gain as much as 48%.

NEW YORK, Feb. 3, 2025 /PRNewswire/ -- As the healthcare sector embarks on a transformative year ahead, AlphaSense, the leading market intelligence and search platform, continues to solidify its ...

Strength in the Electronic Instruments Group segment on the back of benefits from Virtek Vision International, Navitar, Alphasense ... expert as the #1 favorite stock to gain +100% or more ...

The shares closed the day at $367.74, down 8.3% from previous close. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the ...

Nvidia stock (NVDA) clawed back some losses Tuesday after Monday's DeepSeek-fueled 17% crash. At the end of the trading day, Nvidia stock stood 8.9% higher at $128.99. The move helped stoke a ...

Televisions broadcast stock market information outside the Nasdaq MarketSite in New York on Monday, Jan. 27, 2025. [Photo: Yuki Iwamura/Bloomberg via Getty Images] Yesterday, shockwaves rippled ...